Head-to-head evidence
cagrilintide/semaglutide vs ecnoglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: March 2027 · NCT07011667 (registry estimate)
ecnoglutide
Marketed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 664 adults with overweight or obesity. Ecnoglutide 2.4 mg produced a significantly greater reduction in body weight than placebo at week 40, -13.2% vs +0.1%, p<0.0001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT07553299 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · ecnoglutide's landscape